Image

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Testing LBP-EC01 for drug-resistant E. Coli UTIs.

Recruiting
18-75 years
Female
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates a new treatment, LBP-EC01, for urinary tract infections (UTIs) caused by drug-resistant E. coli. A UTI is an infection in any part of the urinary system, often causing pain and discomfort. Drug-resistant means the bacteria don't respond to common antibiotics. LBP-EC01 is a recombinant bacteriophage cocktail, which is a mix of viruses that can attack bacteria.

The study has two parts. In the first part, 30 patients will help determine the best dose. In the second part, 288 patients will either receive LBP-EC01 with an antibiotic or a placebo (a look-alike pill with no active ingredient) with an antibiotic. All participants will have an acute, uncomplicated UTI at the start.

  • Participation: Requires attending regular visits and following the study plan.
  • Eligibility: Must have had a UTI caused by drug-resistant E. coli in the past year.
  • Risks: Includes potential side effects and commitments to study rules.

Participants must agree not to use other treatments for their UTI during the study and are required to use effective birth control if applicable.

Print
Study details
    Urinary Tract Infections

NCT05488340

Locus Biosciences

1 March 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.